Viewing Study NCT06106802


Ignite Creation Date: 2025-12-25 @ 3:57 AM
Ignite Modification Date: 2025-12-26 @ 2:48 AM
Study NCT ID: NCT06106802
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-10-30
First Post: 2023-10-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Sponsor: Samsung Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module